
Biogen Alzheimer Drug Slows Decline by 38 Percent
Biogen announced two-year trial data showing its experimental drug diranersen slowed cognitive decline in early Alzheimer patients by 38 percent. The spinal injection targets toxic tau protein without causing dangerous brain swelling.
Xurve View
Insights:
Xurve View

Biogen reported that its experimental anti-tau drug slowed cognitive decline by 38% after two years in early Alzheimer's patients. The new trial data, presented on Tuesday, shows that the clinical benefits of the treatment increased over time. This development marks a milestone for targeting tau proteins in neurodegenerative disease research.









